hVIVO (LON:HVO) Stock Price Down 46.3% – Time to Sell?

Shares of hVIVO plc (LON:HVO) were down 46.3% during trading on Saturday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). Approximately 83,062,000 shares changed hands during mid-day trading, an increase of 2,325% from the average daily volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).

Analyst Ratings Changes

Separately, Shore Capital reiterated a “buy” rating on shares of hVIVO in a research note on Friday.

hVIVO Price Performance

The firm’s 50-day moving average is GBX 16.16 and its 200-day moving average is GBX 18.04. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The company has a market capitalization of £61.56 million, a P/E ratio of 3.59 and a beta of 0.97.

hVIVO (LON:HVO) last announced its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Analysts predict that hVIVO plc will post 1.5492958 EPS for the current fiscal year.

Insider Activity at hVIVO

In other hVIVO news, insider Yamin Mo’ Khan sold 3,062,246 shares of hVIVO stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total transaction of £520,581.82 ($700,648.48). 14.03% of the stock is currently owned by company insiders.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.